Steven Kregel, PhD
Assistant Professor
Cancer Biology
Research Interests:
- Prostate cancer and urologic research
- Androgen receptor signaling
- Hormone therapies and resistance
- Tumor immune microenvironment
Bio
Our research focuses on developing novel models for the study of metastatic castration resistant prostate cancer (mCRPC), with an emphasis on targeting the androgen receptor (AR) signaling pathway. Utilizing advanced techniques in genetics, genomics, animal models, molecular biology, and translational medicine, our research program addresses pressing issues in prostate cancer biology. Specifically, we are generating more clinically relevant mouse models utilizing human cancer and human immune systems to investigate the role of the immune system in mediating responses to AR-targeted therapies, studying how prostate cancer metastasizes and evades immunotherapy and hormone therapies, and the basic biological functions of AR and other nuclear hormone receptors. Currently, the lab is funded by the Prostate Cancer Foundation to develop and use this first immunocompetent model of human prostate cancer with the ability to metastasize to clinically relevant locations like the bone, but also responds to standard-of-care hormonal therapies and immunotherapy.
Institute of Translation Medicine video highlighting Dr. Kregel's research. Click here to view.
Education
- BS in Biological Chemistry, BA in Biology, BA n Chemistry, University of Chicago
- MS in Translational Science and Molecular Medicine, University of Chicago
- PhD in Cancer Biology, University of Chicago
- Postdoctoral fellowship in Prostate Cancer Biology, University of Michigan
Research Interests
- Prostate Cancer and Urologic Research
- Androgen receptor signaling
- Hormone therapies and resistance
- Tumor immune microenvironment
Publications/Research Listings
- Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation Kostlan, RJ; Phoenix JT; Budreika, A; Ferrari, M; Khurana N; Moskal R; Kregel S; Mol Cancer Res (2024) https://doi.org/10.1158/1541-7786.MCR-23-0904
- SOX2 mediates metabolic reprogramming of prostate cancer cells de Wet L; Williams A; Gillard M; Kregel S; Lamperis S; Gutgesell LC; Vellky JE; Brown R; Conger K; Paner GP; Wang H; Platz EA; De Marzo AM; Mu P; Coloff JL; Szmulewitz RZ; Vander Griend DJ Oncogene 2022 Feb;41(8):1190-1202. doi: 10.1038/s41388-021-02157-x. Epub 2022 Jan 24. Erratum in: Oncogene. 2022 Feb 10;: PMID: 35067686; PMCID: PMC8858874
- Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Xiao L; Parolia A; Qiao Y; Bawa P; Eyunni S; Mannan R; Carson SE; Chang Y; Wang X; Zhang Y; Vo JN; Kregel S; Simko SA; Delekta AD; Jaber M; Zheng H; Apel IJ; McMurry L; Su F; Wang R; Zelenka-Wang S; Sasmal S; Khare L; Mukherjee S; Abbineni C; Aithal K; Bhakta MS; Ghurye J; Cao X; Navone NM; Nesvizhskii AI; Mehra R; Vaishampayan U; Blanchette M; Wang Y; Samajdar S; Ramachandra M; Chinnaiyan AM Nature 2022 Jan;601(7893):434-439. doi: 10.1038/s41586-021-04246-z. Epub 2021 Dec 22. PMID: 34937944; PMCID: PMC8770127
- PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer Darga EP; Dolce EM; Fang F; Kidwell KM; Gersch CL; Kregel S; Thomas DG; Gill A; Brown ME; Gross S; Connelly M; Holinstat M; Cobain EF; Rae JM; Hayes DF; Paoletti C PLoS One 2021 Nov 15;16(11):e0260124. doi: 10.1371/journal.pone.0260124. PMID: 34780566; PMCID: PMC8592410
- Biologically informed deep neural network for prostate cancer discovery Elmarakeby HA; Hwang J; Arafeh R; Crowdis J; Gang S; Liu D; AlDubayan SH; Salari K; Kregel S; Richter C; Arnoff TE; Park J; Hahn WC; Van Allen EM Nature 2021 Oct;598(7880):348-352. doi: 10.1038/s41586-021-03922-4. Epub 2021 Sep 22. PMID: 34552244; PMCID: PMC8514339
- Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2 Qiao Y; Wang XM; Mannan R; Pitchiaya S; Zhang Y; Wotring JW; Xiao L; Robinson DR; Wu YM; Tien JC; Cao X; Simko SA; Apel IJ; Bawa P; Kregel S; Narayanan SP; Raskind G; Ellison SJ; Parolia A; Zelenka-Wang S; McMurry L; Su F; Wang R; Cheng Y; Delekta AD; Mei Z; Pretto CD; Wang S; Mehra R; Sexton JZ; Chinnaiyan AM Proceedings of the National Academy of Science U S A 2020 Dec 11;118(1):e2021450118. doi: 10.1073/pnas.2021450118. Epub ahead of print. PMID: 33310900; PMCID: PMC7817128
- Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element Kregel S; Bagamasbad P; He S; LaPensee E; Raji Y; Brogley M; Chinnaiyan A; Cieslik M; Robins DM Nucleic Acids Research 2020 May 21;48(9):4741-4755. doi: 10.1093/nar/gkaa178. PMID: 32198885; PMCID: PMC7229860
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM Neoplasia. 2020 Feb;22(2):111-119. doi: 10.1016/j.neo.2019.12.003. Epub 2020 Jan 10. PMID: 31931431; PMCID: PMC6957805
- Functional and mechanistic interrogation of BET bromodomain degraders for the treatment of metastatic castration-resistant prostate cancer Kregel S; Malik R; Asangani IA; Wilder-Romans K; Rajendiran T; Xiao L; Vo JN; Soni T; Cieslik M; Fernadez-Salas E; Zhou B; Cao X; Speers C; Wang S; Chinnaiyan AM Clinical Cancer Research 2019 Jul 1;25(13):4038-4048. doi: 10.1158/1078-0432.CCR-18-3776. Epub 2019 Mar 27. PMID: 30918020; PMCID: PMC6606381
- Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer Urbanucci A; Barfeld SJ; Kytölä V; Itkonen HM; Coleman IM; Vodák D; Sjöblom L; Sheng X; Tolonen T; Minner S; Burdelski C; Kivinummi KK; Kohvakka A; Kregel S; Takhar M; Alshalalfa M; Davicioni E; Erho N; Lloyd P; Karnes RJ; Ross AE; Schaeffer EM; Vander Griend DJ; Knapp S; Corey E; Feng FY; Nelson PS; Saatcioglu F; Knudsen KE; Tammela TLJ; Sauter G; Schlomm T; Nykter M; Visakorpi T; Mills IG Cell Reports 2017 Jun 6;19(10):2045-2059. doi: 10.1016/j.celrep.2017.05.049. PMID: 28591577; PMCID: PMC5675034